Lipocine Inc.
LPCN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.01 | -0.02 | 0.10 |
| FCF Yield | 11.64% | -11.58% | 6.49% | -12.13% |
| EV / EBITDA | -4.55 | -6.58 | 13.00 | -7.79 |
| Quality | ||||
| ROIC | -14.04% | -10.89% | 7.21% | -13.65% |
| Gross Margin | -243.06% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.86 | 1.06 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 324.56% | 87.78% | 181.88% |
| Free Cash Flow Growth | 200.00% | -216.39% | 158.08% | -16.62% |
| Safety | ||||
| Net Debt / EBITDA | 2.53 | 1.62 | -3.69 | 1.37 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1.07 | -1,910.65 | -1,567.29 | -3,017.42 |